Form 4: Allurion Technologies Chief Legal Officer Receives 306,749 Restricted Stock Units

Sentiment:

SEC Form 4 Filing


Allurion Technologies' Chief Legal Officer, Brendan M. Gibbons, was granted 306,749 restricted stock units (RSUs) on November 8, 2024.

Summary

  • Brendan M. Gibbons, Chief Legal Officer of Allurion Technologies, Inc., received 306,749 restricted stock units (RSUs).
  • These RSUs were granted under the company's 2023 Stock Option and Incentive Plan.
  • Each RSU represents the right to receive one share of Allurion's common stock.
  • The RSUs will vest over a two-year period, with 50% vesting on November 8, 2025, and the remaining 50% vesting on November 8, 2026.
  • Vesting is contingent upon Mr. Gibbons' continued service with the company on each vesting date.

Sentiment

Score: 7

Explanation: The document reflects a standard practice of executive compensation, which is generally viewed positively as it aligns management's interests with shareholders. There are no indications of negative sentiment.

Positives

  • The grant of RSUs aligns the Chief Legal Officer's interests with the long-term success of the company.
  • The vesting schedule encourages continued service and commitment from the executive.

Risks

  • The value of the RSUs is dependent on the future performance of Allurion's stock price.
  • If Mr. Gibbons leaves the company before the vesting dates, he will forfeit the unvested RSUs.

Future Outlook

The vesting of the RSUs is contingent upon the continued service of the Chief Legal Officer, indicating a focus on retaining key personnel.

Industry Context

The granting of stock-based compensation is a common practice in the technology and healthcare industries to attract and retain key executives.

Comparison to Industry Standards

  • Granting restricted stock units is a standard practice for executive compensation across various industries, including technology and healthcare.
  • The two-year vesting schedule is also a common approach to ensure long-term commitment from executives.
  • Companies like Medtronic and Boston Scientific also use similar equity-based compensation plans for their executives.

Stakeholder Impact

  • Shareholders may view the RSU grant positively as it incentivizes the Chief Legal Officer to contribute to the company's long-term success.
  • Employees may see this as a positive sign of the company's commitment to its leadership team.

Key Dates

DateDescription
11/08/2024Date of the RSU grant to Brendan M. Gibbons.
11/08/2025First vesting date for 50% of the granted RSUs.
11/08/2026Second vesting date for the remaining 50% of the granted RSUs.
11/12/2024Date the Form 4 was signed by Jennifer Ausrotas, attorney-in-fact.

Keywords

Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Allurion Technologies, Brendan M. Gibbons, Chief Legal Officer, Vesting

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.